Insulin drug maker Novo Nordisk shares slide Add to ...


Reuters |
Show Description
Shares in Danish drug maker Novo Nordisk fell by as much as 15%, after it was hit hard by U.S. regulators' demands for further clinical testing of its new long-acting insulin drug Tresiba. Joanna Partridge reports

More from this section

Editor's Picks

Globe Shows »

Put your best foot forward with our expert advice